CN111303287B - anti-CD19 fully human antibody or antibody fragment, chimeric antigen receptor thereof and application thereof - Google Patents

Abstract

The invention discloses a fully humanized antibody or antibody fragment of anti-CD19, a chimeric antigen receptor thereof and application thereof. The antibody or antibody fragment or the nucleic acid encoding the antibody or antibody fragment can be used for preparing host cells, lentiviral plasmids, tumor diagnosis, targeting antitumor drugs and the like. The antibody or antibody fragment disclosed by the invention can be combined with human CD19 protein with high specificity.

Description

anti-CD19 fully human antibody or antibody fragment, chimeric antigen receptor thereof and application thereof

The invention is applied by division, the original application number is 201911234429.6, the original application date is 12/5/2019, and the invention name is 'fully human antibody or antibody fragment aiming at CD19, chimeric antigen receptor and application'.

Technical Field

The invention relates to the technical field of biological medicines, in particular to a fully humanized antibody or antibody fragment of anti-CD19, a chimeric antigen receptor thereof and application thereof.

Background

B cell malignancies are common hematological malignancies, first-line clinical therapy has a certain efficacy, but high recurrence rate and poor prognosis, and CD19 has received great attention as a molecular target for immunotherapy of B cell malignancies. CD19 is a normal and malignant B lymphocyte specific surface protein that plays an important role in the development, proliferation and differentiation of B cells, as well as in malignant transformation. The specificity of CD19 in B lymphocyte expression and the broad spectrum of malignancy expression thus make it a potential molecular target for B lymphocyte malignancy immunotherapy.

Various immunotherapeutic strategies targeting CD19, including Fc fragment-modified antibodies, antibody-drug conjugates, bispecific antibodies, chimeric antigen receptor-modified T cells, and the like, are being developed in the laboratory and in the clinic, achieving encouraging therapeutic effects in leukemia and lymphoma, and strongly driving the development of targeted immunotherapy.

CAR-T is collectively referred to as Chimeric Antigen Receptor T-Cell Immunotherapy (Chimeric Antigen Receptor T-Cell Immunotherapy). Novel cell therapies with significant efficacy in the treatment of acute leukemias and non-hodgkin's lymphomas are considered to be one of the most promising approaches to tumor treatment. CAR-T technology has undergone a lengthy evolution process, a new type of cell therapy that has emerged for many years but has only been improved in recent years for clinical use.

The key to this new therapeutic strategy is the recognition of an artificial receptor called a Chimeric Antigen Receptor (CAR) for the target cell, and the ability of patient T cells to express this CAR after genetic modification. In human clinical trials, scientists have extracted some of the T cells from patients through a dialysis-like process and then genetically modified in the laboratory to introduce genes encoding the CAR so that the T cells can express the new receptor. These genetically modified T cells are propagated in the laboratory and subsequently perfused back into the patient. These T cells bind to the molecule on the surface of the target cell using the CAR receptor they express, and this binding triggers an internal signal generation which then activates the T cells so strongly that they rapidly destroy the target cell.

Disclosure of Invention

The invention aims to provide a fully human antibody or antibody fragment of anti-CD19, a chimeric antigen receptor thereof and application thereof. The antibody or antibody fragment has high targeting property, can be specifically combined with human-derived CD19 protein, and can be used for treating hematological cancers related to CD19 expression.

In order to achieve the above objects, the present invention provides a fully human antibody or antibody fragment of anti-CD19, comprising: a heavy chain variable region and a light chain variable region; the heavy chain variable region comprises three complementarity determining regions HCDR1, HCDR2 and HCDR 3; the light chain variable region comprises three complementarity determining regions LCDR1, LCDR2 and LCDR 3; the amino acid sequences of the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 are respectively shown as SEQ ID NO: 3. 4, 5, 6, 7 and 8.

Preferably, the anti-CD19 binding domain of the antibody or antibody fragment is an scFv and the amino acid sequence of the anti-CD19 binding domain comprises SEQ ID NO: 2, or a functional homologue thereof having 95-99% identity to the sequence.

Preferably, the amino acid sequence of said scFv comprises a heavy chain variable region of SEQ ID NO: 2, and the modified amino acid is at least one, two or three but not more than 30.

Preferably, the anti-CD19 binding domain of the antibody or antibody fragment is an scFv, the nucleic acid sequence of which comprises the amino acid sequence of SEQ ID NO: 1, or a functional homologue thereof having 95-99% identity to said sequence.

Preferably, the scFv comprises a heavy chain variable region of SEQ ID NO: 1, and at least one, two or three but not more than 30 modified nucleic acids.

The invention also provides a chimeric antigen receptor which contains the fully human antibody or antibody fragment of the anti-CD 19.

Preferably, the chimeric antigen receptor comprises, connected in sequence: a signal peptide sequence, a CD19 binding domain, a detection tag, a hinge region and a transmembrane domain, and a functional signaling domain:

the signal peptide sequence comprises CSF2 RA;

the detection tag comprises C-myc; said CD19 binding domain comprises an scFv comprising a fully human antibody or antibody fragment of said anti-CD 19;

the hinge region and transmembrane domain comprise: hinge region Hinge TM and transmembrane structure CD8,

the functional signaling domain comprises: CD28, 4-1BB and CD3 Zeta connected in sequence.

The invention also provides a host cell comprising the chimeric antigen receptor described above.

The invention also provides a lentivirus plasmid, which comprises a nucleotide sequence of the fully human antibody or antibody fragment capable of encoding the anti-CD 19.

The invention also provides application of the fully humanized antibody or antibody fragment of the anti-CD19, and the fully humanized antibody or antibody fragment of the anti-CD19 is used for preparing tumor diagnosis and targeting antitumor drugs.

Has the advantages that:

(1) the antibody or antibody fragment of the invention can be combined with human CD19 protein with high specificity, the chimeric antigen receptor technology (CAR-T technology) is utilized to engineer the human antibody fragment which is integrated in CAR and is combined with CD19 in T cells, and the obtained chimeric antigen receptor T cells can be used for treating hematological cancers related to CD19 expression.

(2) The chimeric antigen receptor of the invention can target a malignant B cell tumor disease cell surface marker molecule CD 19.

Drawings

FIG. 1 is a lentivirus sublibrary plasmid map.

FIG. 2 shows the result of green fluorescence signal of lentivirus sublibrary package.

FIG. 3 shows the result of the Jurkat fluorescence signal of lentivirus-infected host cells.

FIG. 4a shows the blank host cell jurkat as a control, and the cells expressing the green fluorescence reporter gene are obtained by cell sorting, i.e., the cell population in Q2\ Q3 in the right picture.

FIG. 4b shows that the host cell jurkat expressing the CAR gene obtained by sorting was co-incubated with the negative cell K562 and the positive cell Raji, and the cells expressing the APC fluorescence signal were obtained by cell sorting using the negative cell as a control, i.e., the right cell population in the right panel.

FIG. 5 shows that the purified antibody 4-H3 can well recognize the CD19 antigen on the surface of Raji cells, which is obtained by using Raji cells highly expressing CD19 as a blank control and FMC63 as a positive control.

FIG. 6 shows activation of jurkat effector host cells incubated with target cells (detection of anti-CD69-APC fluorescent antibody) indicating that the fully human anti-CD19 antibody 4-H3 is able to better recognize CD19 on the surface of Raji cells.

Detailed Description

Definition of terms

An "antibody" refers to a glycoprotein comprising at least two heavy (H) chains and two light (L) chains that are linked to each other by disulfide bonds, or an antigen-binding portion thereof. Antibodies include single chain antibodies.

The "heavy chain" consists of a heavy chain variable region (VH) and a heavy chain constant region.

The "light chain" consists of a light chain variable region (VL) and a light chain constant region.

"scFv": the single-chain antibody (single-chain antibody fragment) is formed by connecting an antibody heavy chain variable region and a light chain variable region through a short peptide (linker) of 15-20 amino acids.

The "heavy chain variable region" and "light chain variable region" can be further subdivided into hypervariable regions, termed "complementarity determining regions" (CDRs), interspersed with more conserved regions termed "framework regions" (FRs). Each VH and VL consists of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FRI, CDRl, FR2, CDR2, FR3, CDR3, FR4, the variable regions of the heavy and light chains contain binding domains that can interact with antigens. In the present invention, CDRL, CDR2, CDR3 of the heavy chain variable region are respectively represented as HCDR1, HCDR2 and HCDR 3; the CDRL, CDR2, CDR3 of the light chain variable region are denoted LCDR1, LCDR2 and LCDR3, respectively.

The "constant region" may mediate the binding of the immunoglobulin to host tissues or factors.

An "antigen binding domain" refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen (e.g., CD 19).

"monoclonal antibody" refers to a preparation of antibody molecules consisting of a single molecule. Monoclonal antibody compositions exhibit specific binding and affinity for a particular epitope (the portion of the antigen specifically recognized by the antigen receptor).

A "chimeric antigen receptor" consists of an extracellular antigen-binding region (consisting of a light chain and a heavy chain derived from a monoclonal antibody, joined by a flexible hinge region in between to form a single chain antibody, a transmembrane region, and an intracellular signaling region.

"CAR-T technology" refers to chimeric antigen receptor T cell immunotherapy. The scFv for recognizing tumor-associated antigen and an intracellular signal domain 'immunoreceptor tyrosine activation motif' are subjected to in vitro gene recombination to generate recombinant plasmids, the recombinant plasmids are transfected into T cells of a patient in vitro by a transfection technology to enable the T cells of the patient to express a tumor antigen receptor, and the transfected T cells are purified and amplified in a large scale and are called chimeric antigen receptor T cells.

"95-99% identity" means homology of 95% or more (optimally 98% or more).

"modification" is a variation of an amino acid or nucleotide, including deletion, insertion and/or substitution of one or more (usually 1 to 50, preferably 1 to 30, more preferably 1 to 20, most preferably 1 to 10) amino acids or nucleotides, and addition of one or several (usually less than 20, preferably less than 10, more preferably less than 5) amino acids or nucleotides at the C-terminal and/or N-terminal, without changing the function of the protein or nucleic acid.

The invention provides a fully human antibody or antibody fragment aiming at CD19, wherein the anti-CD19 binding domain of the antibody or antibody fragment is scFv, and the amino acid sequence of the scFv is specifically shown in Table 1.

TABLE 1 amino acid sequence of scFv

The nucleic acid sequence encoding the scFv provided by the invention comprises SEQ ID NO: 1, and after the translation of the sequence into an amino acid sequence according to codons corresponding to bases in each sequence, the corresponding amino acid sequences of the scFv are respectively SEQ ID NO: 2, or a pharmaceutically acceptable salt thereof.

The technical solution of the present invention is further described below with reference to the accompanying drawings and examples.

Some of the material sources are illustrated below:

CD19 protein: human CD19 (available from Acrobiosters, cat # CD 9-H8259).

Phage antibody library of human single-chain antibodies: constructed by the firm floros pharmaceutical technology ltd.

Streptavidin magnetic beads: purchased from Invitrogen corporation.

Enzyme-linked immunosorbent assay microplate: a96-well half-well low-turbine microplate (available from Corning Corp.).

Anti-M13 HRP antibody: from Thermo Fisher, inc.

M13 helper phage: purchased from Invitrogen corporation.

SOC culture medium: purchased from Shanghai Producers.

pCGMT phage vector: available from Addgene, Inc.

XL1-blue bacterium: purchased from agilent corporation under item number 200228.

LB solid medium plate: 5g of yeast extract, 10g of peptone, 10g of sodium chloride and 10g of agar powder were dissolved in 1L of double distilled water, autoclaved at 121 ℃ and poured onto a plate.

Developing solution ABTS solution: available from Thermo Fisher corporation under the designation 002024.

Gelred nucleic acid dye: from Thermo Fisher, inc.

pFUSE expression vector: purchased from Invitrogen corporation.

Plasmid extraction kit: purchased from QIAGEN corporation.

Restriction enzymes: purchased from Takara corporation.

And (3) recombinase: purchased from Novoprotein, inc.

lipo3000 reagent: from Thermo Fisher, inc.

Polybrene reagent: from Thermo Fisher, inc.

RMPI 1640 medium: purchased from gibco.

DMEM medium: purchased from gibco.

Myc-Tag (9B11) Mouse mAb (PE Conjugate): purchased from cell signalling, inc.

293Fectin transfection reagent: purchased from Invitrogen, cat # 12347500.

293Freestyle suspension cells: from Thermo Fisher, inc.

Immunoglobulin IgG1 constant region Fc fragment: purchased from tsingse corporation, tokyo.

Protein quantification kit by BCA method: purchased from Pierce, cat # 23252.

CBS antigen fixing solution: 1.59g of Na₂CO₃And 2.93g NaHCO₃Dissolved in 1L of water and adjusted to pH 9.6.

Anti-Human Fc HRP secondary antibody: from Thermo Fisher, inc.

96-well bottom-pass plate: purchased from Corning corporation.

Biacore instrument: purchased from GE, T200.

Protein A chip: purchased from GE company.

Examples

Construction of directional anti-CD19 fully human antibody sublibrary

1.1 screening and obtaining the anti-human CD19 specific antibody sub-library based on a fully human natural antibody library which is independently constructed by the company Fisher by utilizing a phage display technology.

(1) Establishing a phage antibody library of the fully human single-chain antibody:

designing primers to amplify a heavy chain variable region and a light chain variable region of an antibody, connecting the heavy chain variable region and the light chain variable region by a Linker in an overlapping extension PCR mode to obtain a full-length PCR product, carrying out enzyme digestion on the PCR product and a pCGMT3 phagemid vector by SfiI, electrically transforming a connected transformation product into XL1-blue competent cells, adding 3mL of SOC culture medium into the competent cells, culturing at 30 ℃ for 1h, adding ampicillin with the final concentration of 50 mu g/mL and 20mL of 10 mu g/mL tetracycline solution, and carrying out shake culture at 37 ℃ for 2 h.

Then adding the mixture to a concentration of 10¹³50 μ L of VCSM13 helper phage/mL was incubated at room temperature for 1h with gentle shaking every 10 min. Shaking culture at 37 deg.C for 2h, adding kanamycin to final concentration of 70 μ g/mL, and overnight culture at 30 deg.C. Centrifuging to collect supernatant, adding 10% PEG-8000/sodium chloride solution (PEG is polyethylene glycol), centrifuging at 4 deg.C in ice bath for 1h at 8000rpm, discarding supernatant, and dissolving with 2mL PBS solution (phosphate buffer) containing 1% BSA (bovine serum albumin)Precipitating, centrifuging and collecting supernatant, namely obtaining the phage antibody library of the fully human single-chain antibody.

(2) Antibody library screening:

take 200. mu.L (containing phage 1X 10)¹²mL) phage antibody library expressing fully human single chain antibody was mixed with 5 μ g of CD19 antigen, incubated at room temperature for 2 hours, 50 μ L of streptavidin magnetic beads were added, antigen-bound phage were captured by the streptavidin magnetic beads, unbound phage were removed after rinsing with 0.5% Tween-20 in PBS (phosphate buffered saline), and phage stably bound to magnetic beads were eluted with hydrochloric acid glycine solution (pH 2.2) for use.

Inoculating 20mL of XL1-Blue bacteria to OD₆₀₀(light absorption value at 600nm wavelength, optical density) reaches 0.6, adding the above eluted phage, standing with XL1-Blue bacteria at 37 deg.C for 30min, spreading the bacterial solution on ampicillin resistant plate, eluting and collecting thallus on ampicillin resistant plate the next day, infecting 1 × 10¹²pfu/mL (pfu, plaque forming unit) of M13 helper phage was amplified and subjected to the next round of selection, for a total of 1-2 rounds of selection.

And (3) coating XL1-Blue bacterial liquid infecting phage on an LB solid culture medium plate with the diameter of 15cm and the resistance of ampicillin, collecting bacterial liquid on the ampicillin resistance plate after culture, and extracting plasmids by using a small root plasmid extraction medium kit (DP106) to obtain the anti-human CD19 specific antibody sublibrary.

1.2 lentivirus vector sublibrary construction:

the plasmid map of the lentivirus sublibrary can be seen in FIG. 1. The plasmid map includes a signal peptide sequence, CD19 binding domain, detection tag, hinge and transmembrane domains, functional signaling domain, regulatory peptide, and fluorescent reporter: the signal peptide sequence comprises CSF2 RA; the detection tag comprises C-myc; said CD19 binding domain comprises an scFv comprising said fully human anti-CD19 antibody or antibody fragment; the hinge region and transmembrane domain comprise: hinge region Hinge TM and transmembrane structure CD8, said functional signaling domain comprising: CD28, 4-1BB and CD3 Zeta connected in sequence. T2A is a regulatory peptide, and EGFP is a fluorescent reporter gene.

(1) Taking 10 mu g of anti-human CD19 antibody sub-library plasmid and 2 mu g of lentiviral vector plasmid, adding 5 mu LSfiI for enzyme digestion, carrying out enzyme digestion in water bath at 50 ℃ for 2h, and then carrying out gel recovery on the enzyme digestion product;

(2) taking an anti-human CD19 antibody sub-library plasmid sfiI I enzyme digestion product and a lentiviral vector plasmid sfiI enzyme digestion product, connecting for 5h at 16 ℃, and concentrating the connection product to 20 mu L by using a takara fragment purification kit;

(3) taking the ligation product to be transferred into 100 mu L of escherichia coli XL1-Blue competent cells by electroporation per 4 mu L, and the specific process is as follows:

a. taking out the competent cells from a refrigerator at the temperature of-80 ℃, and unfreezing the competent cells on ice;

b. putting 4 mu L of purified plasmid into a 1.5mL centrifuge tube, and placing the centrifuge tube and a 0.1cm electrode cup on ice for precooling;

c. transferring 100 μ L of thawed competent cells to the above 1.5mL centrifuge tube, carefully mixing, and standing on ice for 10 min;

d. turning on an electric rotating instrument, adjusting to Manual, adjusting the voltage to 2.1KV, transferring the mixture into a precooled electrode cup, lightly knocking the electrode cup to enable the mixture to uniformly enter the bottom of the electrode cup, pushing the electrode cup into the electric rotating instrument, pressing a pulse key, quickly adding 1000 microliter of preheated SOC liquid culture medium into the electric vibrating cup after hearing a buzzer, transferring the electric vibrating cup into a 5mL centrifuge tube after resuspending cells, cleaning the electric vibrating cup with 500 microliter SOC twice, and transferring the electric vibrating cup into the 5mL centrifuge tube;

e.37 ℃ and recovery at 220-250rpm for 1 hour, taking the transformation product to coat a resistant LB plate, placing the plate in a greenhouse at 37 ℃, culturing overnight, and checking the transformation result the next day.

(4) Collecting the bacterial liquid of the LB resistance plate, and extracting plasmids by using a small-volume and medium-volume Tiangen plasmid kit (DP106), namely the anti-human CD19 specific antibody lentivirus sub-library.

(5) Randomly 20 single clones were picked into 14mL culture tubes containing 3mL LB medium and 100 ng/. mu.L ampicillin, incubated overnight at 37 ℃ and confirmed for sequence correctness by Sanger sequencing.

The experimental results are as follows:

sanger sequencing results analysis of the insertion of the complete scFv antibody sequence into the lentiviral vector plasmid.

Second, screening of antibodies specifically binding to CD19 and CAR sequences thereof based on recognition of live cell surface antigen-antibodies

2.1 infection of host cells with a sub-pool of lentiviruses

Introducing the anti-human CD19 specific antibody lentivirus sublibrary constructed in 1.2 into host cells by a cell transfection method of liposome or electrotransformation to obtain recombinant host cells containing specific ligand genes:

2.1.1 Lentiviral packaging

6X 10 cells were transfected 1 day before transfection⁶The 293T cells were seeded in 10cm cell culture dishes and 10ml complete medium without antibiotics was added; preparation of the composite

(1) Mu.g of DNA and 84. mu. L P3000 were diluted in 1.75ml of Opti-MEM medium and gently mixed.

(2) 70ul lipo3000 was diluted in 1.75ml Opti-MEM medium, mixed gently and incubated at room temperature for 5 minutes.

(3) After 5 minutes they were mixed and gently mixed and incubated for 20 min at room temperature; the plate is aspirated and the cells are washed 2 times with PBS or serum-free medium (best); adding 6.5ml DMEM + 10% FBS, adding the compound (the total volume is 3.6ml) into the culture wells, and shaking the culture plate to distribute the compound uniformly; putting the cells into an incubator for incubation for 4-6 h, and then replacing serum-containing culture solution to remove the compound (or not); the expression condition of the transferred gene can be observed after 24-72 h.

(4) After 72 hours the virus was collected, filtered through a 0.45um filter and tested for virus titer.

The experimental results are as follows:

as shown in FIG. 2, a clear green fluorescence signal was observed after 24 hours by fluorescence microscopy with an unconcentrated virus titer > 10⁷IFU/ml。

2.1.2 Lentiviral infection

The collected lentiviruses were infected with host cell jurkat according to MOI gradient.

Centrifuging 300g of host cells for 5min, resuspending the cells, adding a certain volume of packaged virus solution, supplementing 1640+ 10% FBS to 1ml, adding an infection enhancer polybrene to a final concentration of 8ug/ml, uniformly mixing, centrifuging 800g for 1-2 hours, putting into an incubator for culture, preliminarily observing a fluorescence signal by using a fluorescence microscope within 48-72 hours, determining infection efficiency by using flow cytometry, and simultaneously sorting the host cells expressing green fluorescence.

The experimental results are as follows:

as shown in FIG. 3, a clear green fluorescence was observed by fluorescence microscopy after 48 hours, and the infection efficiency by FACS was 22.3%.

FIG. 4a shows that the blank host cell jurkat is used as a control, and the cells expressing the green fluorescence reporter gene, namely the cell population successfully infected with lentivirus in Q2\ Q3 in the right picture, are obtained by cell sorting.

2.2 screening of host cells activated by target cells by flow cytometry

(1) Preparation of Raji and K562 cells: cells were centrifuged at 1000rpm for 5 minutes, the supernatant discarded and resuspended at 1 x 10⁶Per ml; sorted CAR-jurkat cell count 2.5 x 10⁵5ml in total; prepare 12 well plates, add 1.5 x 10 per well⁵Jurkat cells +3 x 10 of⁵Raji cells of (4), 8 wells in total; negative control wells were spiked with 2.5 x 10⁴Jurkat cells +5 x 10⁵K562 cells of (a); adding 1640+ 10% FBS until the culture volume is 2ml, and placing the mixture into an incubator for culture;

(2) transferring the cells in the pore plate into a centrifuge tube, and centrifuging for 5 minutes at 1000 rpm; discard the supernatant and resuspend to 1 × 10 with FACS buffer⁶Density per ml; adding 20 μ l/10 in dark⁶Incubating anti-CD69-APC fluorescent antibody of the cell for 1 hour at 4 ℃, and keeping out of light; FACS buffer washes cells twice, centrifuge at 1000rpm for 5 minutes; resuspending the FACS buffer, filtering the cell by a filter screen into a FACS special test tube, and placing the cell on ice for sorting; the cells obtained after sorting were lysed to obtain DNA for subsequent PCR experiments.

The activation of the effector cell jurkat is demonstrated by detecting the expression of the jurkat surface CD69 molecule, namely the effector cell jurkat can recognize the CD19 antigen on the surface of the target cell, wherein CD69 is the surface antigen expressed earliest after the activation of the T lymphocyte, fig. 4b shows that the host cell jurkat which is sorted to obtain the expression CAR gene is co-incubated with the negative cell K562 and the positive cell Raji respectively, and the cell which expresses the APC fluorescence signal is obtained by cell sorting by taking the negative cell as a control, namely the cell group on the right side in the right picture.

Third, PCR and sequencing analysis

3.1 Effector host cell lysis

Collecting effector host cells obtained by cell sorting, centrifuging at 3000rpm for 5min, discarding supernatant of culture medium, adding cell lysate 20 μ l, mixing uniformly for 15s, and incubating in 65 deg.C metal bath for 6 min; mixing for 15s, transferring to 98 deg.C metal bath, incubating for 2-5min, storing the cleaved DNA at-20 deg.C, storing at-70 deg.C for long term, and taking 5 μ l or less amount for directly using in PCR amplification sequence.

3.2PCR and sequencing analysis

(1) Taking 1 mul of DNA obtained by cell lysis as a PCR template, wherein the PCR reaction system is as follows: 5 XPrimeSTAR GXL PCR buffer 10. mu.L, dNTPs mix 4. mu.L (2.5 mM), DNA template 2. mu.L, upstream and downstream primers 1.5. mu.L each,

GXL DNA polymerase 1. mu.L, ultrapure water was added to 50. mu.L.

(2) And (3) PCR reaction conditions: denaturation at 94 deg.C for 5 min; at 98 ℃ for 10s, 55 ℃/60 ℃ for 15s, and 68 ℃ for 1kb/min, for 30 cycles; extension at 72 ℃ for 10 min.

(3) And (3) verifying the correct size of the PCR product through agarose gel electrophoresis, and then performing gel cutting recovery by using a gel recovery kit.

(4) Taking 10 mu l of the recovered PCR product, adding 5 mu l of SfiI for enzyme digestion, carrying out enzyme digestion in water bath at 50 ℃ for 2h, and then recovering the enzyme digestion product; PCR sfII enzyme digestion recovery product and lentiviral vector plasmid enzyme digestion product are connected for 5h at 16 ℃, the connection product is taken and transferred into 100 mul escherichia coli stbl3 competent cells, activated for 1h at 37 ℃, coated with an ampicillin (LB) plate, cultured overnight at 37 ℃, then 100 monoclonals are picked up and subjected to sanger sequencing.

The experimental results are as follows: single colony is picked, 8 antibody sequences C13, C20, C25, C135, 1-B11, 4-H3, 3-F11 and 3-H5 with high enrichment degree are obtained by extracting plasmids and sequencing the plasmids by sanger.

Fourth, the ability of the anti-CD19 fully human antibody 4-H3 to specifically bind to the CD19 antigen is verified

4.1 detection of the binding Capacity of purified antibody 4-H3 to CD19 antigen

(1) The 4-H3 monoclonal plasmid obtained in the third step is cut by restriction enzyme Sfi I, then is connected, and the fragment is accessed into a pFUSE-hFc expression vector (the pFUSE expression vector acts on the enzyme cutting site through the restriction enzyme Sfi I) by a recombination method, wherein the plasmid vector hFc is a human Fc label, so that the pFUSE expression vector of the antibody is obtained. The specific nucleotide sequence of 4-H3 is: SEQ ID NO: 1, or a fragment thereof.

(2) And (2) mixing the 293Fectin transfection reagent with the eukaryotic antibody expression vector obtained in the above step according to the volume mass ratio of 30 mu L: mixing at a ratio of 30 μ g, adding 30ml 293Freestyle suspension cells, shake culturing at 125rpm and 37 deg.C for 48-72 hr, centrifuging, collecting supernatant, and purifying with HiTrap Protein A HP column

Antibody protein purification was performed on a purifier100 protein purifier to obtain an anti-CD19 single-chain antibody (anti-CD 19 fully human scFv antibody), and finally the antibody concentration was determined with reference to the instruction of the BCA method protein quantification kit.

(3) The expressed and purified antibody is diluted to 200 mu M, and is incubated with human Burkitt's lymphoma cells Raji positive to CD19 antigen expression, the cells are incubated for 1h at 4 ℃ in a turnover manner, the FACS buffer is used for washing the cells twice, goat anti-human-APC antibody (figure 5) diluted by 1:1000 is respectively added, the cells are incubated for 1h at 4 ℃ and washed twice by the FACS buffer, and the cells are resuspended in 100 mu L of the FACS buffer, and the fluorescence signals are detected by a flow cytometer.

The experimental results are as follows:

as shown in fig. 5. FIG. 5 shows that the purified antibody 4-H3 can well recognize the CD19 antigen on the surface of Raji cells by using Raji cells highly expressing CD19 as a blank control and FMC63 as a positive control.

4.2 validation of the ability of anti-CD19-CAR to specifically recognize CD19

(1) The plasmid with the correct anti-CD19-CAR sequence inserted is transfected into the host cell jurkat by lentivirus, and the correct expression of CAR is detected by fluorescent signal;

(2) incubating effector host cells expressing a specific CAR with Raji cells overexpressing the antigen for 24h, and simultaneously incubating effector host cells expressing a specific CAR with K562 cells not expressing the antigen for 24 h; activation of the effector cell jurkat is demonstrated by detecting the expression of the jurkat surface CD69 molecule, i.e., the effector cell jurkat can recognize the CD19 antigen on the surface of the target cell, wherein CD69 is the surface antigen expressed earliest after activation of T lymphocytes;

(3) after centrifugation, FACS buffer is used for resuspending cells, anti-CD69-APC antibody is added into the co-incubated host cells and Raji cells/host cells and K562 cells, 4 mu L/sample is used for resuspending the cells, incubation is carried out for 1h at 4 ℃, the cells are washed for 2 times by using flow buffer, 0.1mL of flow buffer is used for resuspension, a negative control is set by using the host cells/K562 which does not express CD19 as a negative control, the host cells/Raji cells as a blank control, FMC63 as a positive control, and the fluorescence signal of APC (activation signal CD69 expressed by Jurkat) is used for detecting the activation ratio of the host cells, namely the capability of anti-CD19-CAR for specifically recognizing CD19 antigen.

The experimental results are as follows:

as shown in FIG. 6, the activation of jurkat (detection of anti-CD69-APC fluorescent antibody) of effector host cells incubated with target cells experimentally demonstrated that the fully human antibody 4-H3 against CD19 could better recognize CD19 on the surface of Raji cells.

While the present invention has been described in detail with reference to the preferred embodiments, it should be understood that the above description should not be taken as limiting the invention. Various modifications and alterations to this invention will become apparent to those skilled in the art upon reading the foregoing description. Accordingly, the scope of the invention should be determined from the following claims.

Sequence listing

<110> Changzhou Fislos pharmaceutical technology Ltd

<120> fully human antibody or antibody fragment of anti-CD19, chimeric antigen receptor and application thereof

<160> 8

<170> SIPOSequenceListing 1.0

<210> 1

<211> 759

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<400> 1

atggcacagg ttcagctggt acagtctggg gctgaggtga agaagcctgg gtcctcggtg 60

aaggtctcct gcaaggcttc tggaggcacc ttcagcagct atgctatcag ctgggtgcga 120

caggcccctg gacaagggct tgagtggatg ggagggatca tccctatctt tggtacagca 180

aactacgcac agaagttcca gggcagagtc acgattaccg cggacgaatc cacgagcaca 240

gcctacatgg agctgagcag cctgagatct gaggacacgg ccgtgtatta ctgtgcgaga 300

gagctgggga tgggtggcta ctactactac ggtatggacg tctggggcca ggggaccacg 360

gtcaccgtct cctcaggcgg cggcggctct ggcggaggtg gcagcggcgg tggcggatcc 420

gacatcgtga tgacccagtc tccactctcc ctggccgtca cccctggaga gccggcctcc 480

atctcctgca ggtctagtca gagcctcctg catactaatg catacaacta tttggattgg 540

tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc 600

tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 660

agcagagtgg aggctgagga tgttggggtt tattactgca tgcaaggtcg acaaactccg 720

tacacttttg gccaagggac caaagtggat atcaaacgt 759

<210> 2

<211> 253

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<400> 2

Met Ala Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro

1 5 10 15

Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser

20 25 30

Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu

35 40 45

Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln

50 55 60

Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr

65 70 75 80

Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Ala Arg Glu Leu Gly Met Gly Gly Tyr Tyr Tyr Tyr Gly Met

100 105 110

Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly

115 120 125

Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met

130 135 140

Thr Gln Ser Pro Leu Ser Leu Ala Val Thr Pro Gly Glu Pro Ala Ser

145 150 155 160

Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Thr Asn Ala Tyr Asn

165 170 175

Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu

180 185 190

Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser

195 200 205

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu

210 215 220

Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Arg Gln Thr Pro

225 230 235 240

Tyr Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys Arg

245 250

<210> 3

<211> 8

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<400> 3

Gly Gly Thr Phe Ser Ser Tyr Ala

1 5

<210> 4

<211> 8

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<400> 4

Ile Ile Pro Ile Phe Gly Thr Ala

1 5

<210> 5

<211> 16

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<400> 5

Ala Arg Glu Leu Gly Met Gly Gly Tyr Tyr Tyr Tyr Gly Met Asp Val

1 5 10 15

<210> 6

<211> 11

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<400> 6

Gln Ser Leu Leu His Thr Asn Ala Tyr Asn Tyr

1 5 10

<210> 7

<211> 3

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<400> 7

Leu Gly Ser

1

<210> 8

<211> 9

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<400> 8

Met Gln Gly Arg Gln Thr Pro Tyr Thr

1 5

Claims (7)

1. A fully human antibody or antibody fragment of Anti-CD19, wherein the antibody or antibody fragment comprises: a heavy chain variable region and a light chain variable region; the heavy chain variable region comprises three complementarity determining regions HCDR1, HCDR2 and HCDR 3; the light chain variable region comprises three complementarity determining regions LCDR1, LCDR2 and LCDR 3;

   the amino acid sequences of the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2 and the LCDR3 are respectively shown as SEQ ID NO: 3. 4, 5, 6, 7 and 8.
2. 2. The fully humanized antibody or antibody fragment of anti-CD19 of claim 1, wherein the anti-CD19 binding domain of said antibody or antibody fragment is an scFv and the amino acid sequence of the anti-CD19 binding domain is SEQ ID NO: 2, or a pharmaceutically acceptable salt thereof.
3. 3. The fully human antibody or antibody fragment of anti-CD19 of claim 1, wherein the anti-CD19 binding domain of said antibody or antibody fragment is an scFv having the nucleic acid sequence of SEQ ID NO: 1, or a fragment thereof.
4. 4. A chimeric antigen receptor comprising a fully human antibody or antibody fragment of anti-CD19 according to any one of claims 1-3.
5. 5. The chimeric antigen receptor according to claim 4, comprising, in sequential order: a signal peptide sequence, a CD19 binding domain, a detection tag, a hinge region and a transmembrane domain, and a functional signaling domain:

   the signal peptide sequence comprises CSF2 RA;

   the detection tag comprises C-myc; said CD19 binding domain comprises an scFv comprising a fully human antibody or antibody fragment of said anti-CD 19;

   the hinge region and transmembrane domain comprise: hinge region Hinge TM and transmembrane structure CD8,

   the functional signaling domain comprises: CD28, 4-1BB and CD3 Zeta connected in sequence.
6. 6. A host cell comprising the chimeric antigen receptor of claim 4 or 5.
7. 7. A lentiviral plasmid comprising a nucleotide sequence encoding a fully human antibody or antibody fragment of anti-CD19 according to any one of claims 1-3.

Images